Inflammatory Bowel Disease Treatment Market Analysis by Drug Class (TNF Inhibitors, Amino Salicylates, Integrin Antagonists, Corticosteroids, and Others); by Disease Indication (Ulcerative Colitis and Crohns Disease); and by Distribution Channel (Hospital, Retail, and Online Pharmacies) - Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Report ID: 4685
  • Published Date: Feb 03, 2023
  • Report Format: PDF, PPT

Companies Dominating the Inflammatory Bowel Disease Treatment Landscape

top-features-companies
    • The Bristol-Myers Squibb Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • AbbVie Inc.
    • Novartis AG
    • UCB Biopharma SRL
    • Biogen Inc.
    • Pfizer, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Celltrion Healthcare Co., Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • The Bristol-Myers Squibb Company to announce that Zeposia (ozanimod) has been given marketing authorization by the European Commission for the treatment of individuals with moderately to highly active ulcerative colitis. Zeposia is orally administered and recommended to be taken once a day. It is the only oral S1P receptor modulator and first innovative method to cure this chronic immune-mediated disease with high efficiency.

  • Bausch Health Companies Inc.- Salix (a subsidiary of Bausch Health Companies Inc.) and Mitsubishi Tanabe Pharma have an exclusive license agreement for the development and marketing of a late-stage investigational S1P modulator for the treatment of inflammatory bowel disease.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4685
  • Published Date: Feb 03, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of Crohn’s disease and growing spending on rare disease are the major factors driving the market growth.

The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023-2033.

Lack of awareness among people regarding inflammatory bowel disease (IBD) are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB Biopharma SRL, Biogen Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, disease indication, distribution channel, and by region.

The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying